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Abstract— Intravenous (IV) lines used in various healthcare
settings pose a risk to patients and their caretakers. A few
common risks include IV lines becoming torn out and coming
into contact with open wounds. We propose to solve this
problem by designing a device that prevents IV and wire
entanglement without obstructing patient care. Our objectives
in identifying a solution include increasing patient comfort,
mobility, and ease of transfer. By solving this issue, other
potential benefits include reducing time spent on non-essential
tasks and reducing the number of personnel needed to transport
patients. We intend to validate our product with healthcare
employees to ensure our solution creates a marketable product
that is affordable, effective, and benefits patients and caregivers
alike.
Keywords— Catheter, Intravenous, Healthcare, Tangle,
Organization
I. INTRODUCTION
The overall goal of this project is to design a medical
device to prevent entangled wires and IV lines during patient
care and transport that does not obstruct patient care.
Ensuring the organization of wires and IV lines may decrease
adverse outcomes such as entanglement of the patient, falls
by both patients and health care providers, and connection
errors or damage of medical equipment.. It’s estimated that
18% of nursing care employee’s injuries can be attributed to
slipping, tripping, and falling [5]. Our objectives to solve this
problem include increasing patient mobility, comfort and
ease of transfer. After interviewing multiple health care
providers, it was noted that every one of them mentioned the
disorganization of IV lines and wires. The issue is especially
prevalent in very ill patients, as they may need many IV drips
or pumps. The disorganization of IV lines could lead to
entanglement and difficulty transferring patients when time is
critical to the patient’s life. It could also lead to unsanitary
conditions, as IV lines can drag across incisions and possibly
introduce pathogens into the wounds.
Initial research on current products that address this issue
was performed. The purpose of this research was to
understand and gather inspiration from previous products,
while also making sure that our design respected their
intellectual property. A handful of designs were found in this
research. All with widely different attaching systems,
collapsing methods, functionalities, materials, and prices.
Some of the designs that closely resembled our ideal solution
would later be used in our competitive technical assessment.
II. USER NEEDS
The first gate’s primary objective was to establish a list of
stakeholder requirements. To do this, we began by reaching
out to medical professionals for interviews. We received
input from two critical care surgery specialists, a critical care
registered nurse (CCRN), and a certified flight registered
nurse (CFRN). These interviews helped us further solidify
our design aspirations while also helping us understand the
main features that would make our product successful. After
looking over our interview notes, seven main points
immediately jumped out. These formed the basis of our
stakeholder requirements. The device should:
1. Prevent entanglement and tension from occurring
2. Be easy to use
3. Reduce the time it takes to transport patients by
facilitating
4. Provide a more sterile environment
5. Provide clarity in organization of tubes/ wires
6. Be affordable/competitive financially
7. Not obstruct the doctors/ nurses from giving care
These newly established stakeholder requirements were
then used to further analyze products on the current market.
By doing this we could understand where previous designs
before us had failed consumer expectations. Additionally,
extensive patent research was conducted to ensure our initial
design ideas did not violate patent law. This patent research
also helped spark new ideas that could be used to address our
stakeholder requirements.
III. DESIGN INPUTS
During the design inputs stage of the design process, the
engineering requirements were extracted and used in the first
phase of the Quality Function Deployment (QFD). The
complete QFD is located in Table 9 in the Appendix. The
first engineering requirement was the device must attach to
the hospital bed with 15 lbf. This came from the customer
requirement of preventing entanglement and tension from
occurring. The best place to organize the wires and IV lines
to prevent entanglement would be a location close to the
patient. If the device was located on the IV pole further away
from the patient, this could allow for easier entanglement of
the lines. The second engineering requirement was to split
the device into 6 sections. This requirement was derived from
the user need of providing clarity in the organization of IV
tubes and wires. The sectioning of the device lets the IV lines
to be organized in a clear manner and they can be labeled and
separated from each other. The third engineering requirement
was that the device would be made of a plastic material and
the material we chose was acrylonitrile butadiene styrene
(ABS). This requirement satisfies the customer requirement
of being affordable and competitive financially. The plastic
material allows the device to be low cost, but also have a
strong base that would not break. The fourth engineering
requirement was the device would be adjustable. This
requirement was derived from the user needs of easy to use
and reduce the time it takes to transport patients. The
adjustability of the device would allow the device to fit to
different styles of hospital beds and attach to different places
on the bed, so it could be easy for a caregiver to move the
device. The last engineering requirement was that the size of
the device would be under six inches. This requirement was
made to satisfy the customer requirement to not obstruct the
medical personnel from taking care of the patient.
A competitive technical assessment was conducted in the
QFD comparing competitor’s devices to the device that we
think we could produce. This part of the QFD was performed
to figure out what devices were already on the market and
determine how those devices fell short of the customer
requirements so we could make a device that better satisfied
the requirements. The devices we ranked ours against are in
the Appendix in Table 9. Each device was ranked on a scale
1-5 on how well they satisfied each customer requirement.
From this assessment, we learned that low cost was an easy
improvement to make to our device and would make our
device better than the competitor’s devices. We also learned
that it is very important that the device does not get in the
way of the doctors and nurses because it could introduce a
new problem instead of fixing an existing one. We decided to
seek a final design that incorporates elements from the
competitor’s portable IV stand design and the IV line
separating design. From the preliminary risk assessment
which is in Figure 8 in the Appendix, all the conceptual
models presented low or moderate risk. The areas of
moderate risks were that the user does not know how to
operate/attach the device, the device falls off the bed, and the
device impedes fluid flow. The design concepts that
presented the lowest risk were concepts that allowed line
slack for patient movement and allowed multiple IV lines and
wires to be distinguished from each other. The recommended
actions from the risk assessment were to label the device
clearly, create a clear and concise user manual, include a
backup mechanism to prevent falls, and include a failsafe to
avoid over compression of IV lines.
IV. DESIGN PROCESS
The third gate was the design process stage. At the
beginning of this stage, we utilized brainstorming techniques
to officially settle on our design. The methods utilized
included Solution Searches and 6-3-5 Brainwriting modified
to work with a group of four. As a group, we selected the
most promising idea from each person and compared each
using a phase two, step one QFD. The QFD enabled us to
rate each design on a scale from 1 to 3 by its potential to
satisfy our engineering and customer requirements. We
settled on a design featuring a screw-in clamp mechanism for
attaching to a bed side, a side protrusion that can hold an IV
pole, and tapered slots on top to hold the medical lines. It
would be superior to the competition by holding more lines,
being more mobile, and having the capability to hold an IV
pole..
With our concept selected we moved on to evaluating
engineering approaches we could use for each component of
the design. We examined existing products and patents to
inform our method of holding the medical tubing. We also
investigated manufacturing methods and materials that would
best suit our product. Additionally, we researched testing
methods to be used to verify our design components.
Next, we developed a QFD parts design matrix. Our
engineering requirements were the inputs, and their
relationships to the broken-out components of our design
were evaluated. Relationships were defined as strong, weak,
or negligible. From these relationships, specifications for
each component were developed based on the research we
conducted into engineering approaches and the criticality of
the relationships. The final matrix is shown in Fig. 1 of the
appendix.
For the final step of this stage, we created a design Failure
Modes and Effects Analysis (FMEA) to improve our design
by evaluating risks. We identified four functions of the design
and broke each out into potential modes of failure and further
into what these failures may cause. Each potential effect of
the failures were assigned numerical ratings for severity,
occurrence, and detectability. The product of these ratings is
known as the Risk Priority Number (RPN). All potential
causes of failures with high RPNs were assigned suggested
actions to improve our design and reduce risk.
V. DESIGN OUTPUTS
The fourth gate was the design outputs stage. Our design
underwent multiple iterations during this time. To begin, we
updated the carabiner attachment mechanism of our initial
CAD model and had it 3D printed through Bierce Library,
shown in Fig. 2 in the appendix.
This alpha prototype was very useful when
communicating our design to others and developing
verification methods. We received feedback on the prototype
from professors and technicians within the Biomedical
Engineering Department that led to further design
development. We also added and edited design elements as a
result of our design verification, including finite element
analyses of simulated stresses. This all led to our more recent
design that incorporates a Velcro fastening system and thumb
slides to secure medical tubing. We had this model 3D
printed as our second alpha prototype, shown in Fig. 3; see
the appendix for all part and assembly drawings, Figs. 4
through 7.
As we added elements to our design, we specified them in
our Bill of Materials (BOM). Decision matrices were utilized
to compare parts and ultimately select the most favorable.
VI. DESIGN VERIFICATION
Verification tests were completed to ensure that the
design outputs met the initial engineering requirements. Test
protocols were created for each test to include the objective
of the test, the rationale, the materials needed, the test
methods, and applicable drawings and test set-ups. The
rationale was developed from research, keeping in mind the
requirement for efficient, quality care in a healthcare setting.
A summary of the verification results for each of the tests are
listed below.
Table 1: A summary of the verification results for each verification test. The
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After implementing each verification test the device was
found to receive a passing score each test, meeting the
minimum requirements within each protocol.
VII. MEDICAL DEVICE
Gate 5 is currently in progress and will be complete by
April 26th. All the parts have been ordered and received for
the prototype. We have started the Validation Testing
discussed in section eight.
VIII. VALIDATION TESTING
Validation tests were completed to ensure the medical
device met the customer requirements. The tests were
conducted using a prototype device in a clinical simulation.
A picture of the device being utilized during validation can
be seen in Figure 8 in the Appendix. Validation documents
were made including the plan, procedure, and validation
report. The validation plans for each customer requirement
can be found in Table 7 located in the Appendix. The detailed
procedure for each validation can also be found in the
Appendix in Table 8. The validation report shows the
outcome of each validation and can be found in Table 9 of the
appendix. If a validation procedure failed to meet acceptance
criteria, a comment was left with an explanation.
IX.   RISK MITIGATION PROCESS
During the design process, a conceptual Failure Modes
and Effects Analysis was created during the second gate to
evaluate potential functions of the device and their respective
failure modes. This was done by first identifying a function
of the device and how the device would fail to perform that
function. The effects of the device failing by each mode
could then be identified. To complete this, the impact of
failure on many variables was investigated including on
patients, hospital staff, and the device itself. A severity score
(Table 4 in the Appendix) was then assigned to each effect of
failure based on the result of the failure. This ranged from a
score of 1, equating with inconvenience or minor discomfort,
to 5, equating with patient death. Potential causes of each
failure were then identified and assigned an occurrence score
(Table 5 in the Appendix) based on how likely that cause was
to happen. This ranged from an occurrence of 1 equating with
a probability of less than 10^-6 to a score of 5 equating with
a probability of ≥ 10^-3. The severity and occurrence scores
were used to assign a classification code to each risk, which
can be found in Table 3. The risk priority number was
assigned by multiplying severity, occurrence, and detection,
to produce a value from 1 to 75.
After a concept was chosen for the device design, a
design FMEA was created during gate 3 using the functions
that were selected for the final prototype. The appropriate
failure modes, effects of failure, and mechanisms of failure
were identified in a manner like that of the conceptual
FMEA. The occurrence and severity scoring system were
also the same. The key risks identified included the device
harming the patient or healthcare staff, the sizing of the
device being wrong so that it does not interface with the
tubing or bed properly, the device is broken by the user, fluid
flow is reduced, the holding mechanism fails, and the device
does not interface with the IV pole properly.
During gate 3 and gate 4, risk mitigation efforts were
made to reduce the identified risks as stated below. It was
determined that a backup mechanism was needed to prevent
the device from falling on the floor or a patient, so a safety
cable will be attached to the device to provide a backup
holding mechanism if the Velcro fails. The device will also
be made in an easily detectable color so it can be quickly
recognized if it falls on the floor. All edges were filleted too,
to prevent injury. A verification test was also required to
ensure the flow difference at the entrance and exit of the
device is no more than 5% different. A verification test was
also done to ensure the strap can withstand a pulling force of
at least 15 pounds. Steps were also taken during gate 5 to
mitigate the risk of incorrect sizing. These included a quality
review that will be performed after manufacturing before the
device is released, labels that will be affixed for the diameters
of tubing that is allowed, and a thorough instruction manual
that will be included. To mitigate the risk of the device
breaking, a thorough instruction manual will be included that
provides detailed use instructions for the healthcare workers.
To mitigate the risk of fluid flow being reduced, a thorough
instruction manual and labeling will be included to give the
maximum diameters of tubing permitted as well as proper
instruction on how to use the device. To mitigate the risk of
the Velcro failing, users are instructed to replace the Velcro
strap after one year of use. To mitigate the risk of the device
not interfacing with the IV pole correctly, instructions on
how to attach the IV pole are included in the instruction
manual. The dimensions of a standard IV pole were also used
in creating the attachment point on the device. A detailed
summary of the risks identified and the respective mitigation
strategies can be found in the Risk Summary Table (Table 9
in the Appendix).
After conducting a risk-benefit analysis, it was
determined that the benefits of the device clearly outweigh
any residual risks. When properly used, the device can
dramatically increase the quality of patient care. Reducing
the entanglement of IV lines improves patient comfort,
mobility, and ease of transportation. The device is also very
likely to reduce patient injury as IV lines won’t be torn out,
or rub and contaminate wounds. The hospital staff will also
be more efficient as the device is likely to reduce time spent
on non-essential tasks and reduce personnel needed to
monitor IV lines and transport patients. The risks to using the
device are mostly minor and/or not very likely to happen.
The device could be used incorrectly and not function
properly, causing IV lines to hang free or the device to fall
and pose a tripping hazard, but these events are not likely to
happen due to the mitigation steps taken. The device could
also restrict fluid flow but this is not very likely, and most
hospitals have monitors that warn staff if IV fluids are not
flowing properly.
X.   MARKETING AND MANUFACTURING CONSIDERATIONS
A. Market Size
If our product successfully solved the stakeholder
problems that we set it is not unreasonable to assume any
interested hospital would purchase one for each staffed bed.
Currently, there are a total of 919,559 staffed hospital beds in
the U.S [4]. Even on 0.1% of U.S hospital beds, we could see
an initial market of 919 sold products.
B. Expected Costs
Our current design consists of 3 distinct components. The
plastic body, the velcro straps, and the rubber tube grips. The
raw material cost of making one plastic body out of ABS was
calculated using the following equation,
PU = PB ρV                                (1)
Where PU is measured in U.S dollars per unit and
represents the cost associated with one device, PB is
measured in U.S dollars per pound and represents the cost per
pound of buying ABS in bulk, ρ is measured in lb/in3 and
represents the density of ABS, and V is measured in in3 and
represents the volume of one device.
We can estimate PB at $0.794/lb [1] and ρ at 3.79E-2
lb/in3 after a simple unit conversion. We can then break down
our plastic body into a cross section, calculate the area of this
cross section, multiply the cross section by the body’s length,
then add a generous 10% waste factor to this volume to
estimate a total volume of 36.7125 in3/part. When plugged
into equation (1) we can estimate an ABS raw material cost
of $1.1055/part.
Our velcro straps are currently purchased off of amazon
for $5.77/part. After researching new suppliers or negotiating
bulk pricing, securing a price below $2.50/part would be a
realistic price goal.
We need 42 sheets of food grade silicone rubber whose
dimensions measure 0.27x1.25 in. This can be calculated as
15.5925in2/part of rubber after a generous 10% waste factor.
We can multiply this by its price per square inch and
determine a final cost of rubber per part. Square inch prices
were researched at $0.058/in2 but could likely get as low as
0.043/in2. Using the later price, we can estimate a food grade
silicone rubber cost of $0.677/part.
Adding the three raw material prices together, we get a
final raw material cost of $4.285/part. We can use this
number to estimate labor cost at $4.285/part and an overhead
of $8.565/part. Taking a 60% margin on $17.13 yields $10.28
of profit per part and a final product cost of $27.41.
C. Competitive Assessment
When compared to other products on the market, a final
price point of $27.41 is extremely competitive. At a relatively
expensive price point we could compare our device to that of
Davinci Medicals, IV Guard IV Line Organizer [6]. This
device is similar to our design but has a more complicated
attachment system, less reliable tube holding, and less
functionality. This device is currently being sold for $499.00.
At a price point comparable to our own, we have the Beata
Clasp [7]. This device has substantially less features than our
device but is currently being sold for $14.95. With a waste
factor of less than 10% and better priced velcro straps, our
device’s price point could easily dip below $27.41. This
would allow it to be even more competitive with devices
such as the Beata Clasp.
XI.    SUMMARY FEASIBILITY DISCUSSION
The need we initially identified was to reduce the
entanglement of medical lines during patient care and
transport. Having not fully completed the design process, we
can only say we expect our design to satisfy this goal. We
developed a design that will hold the medical lines in
separate lanes and hold them there with light contact. Our
team considers the current resultant product to be a
prototype; it may not be made of the same materials or by the
same methods that it would be in large scale manufacturing,
but it accurately showcases all features we want our design to
have. Furthermore, it can be used by stakeholders to test for
requirements, which can further confirm that our design
satisfies the need we initially identified.
XII. DISCUSSION, LESSONS LEARNED, AND CONCLUSIONS
The biggest issue that was present during this design
process was the restrictions we faced due to Covid-19. It was
difficult to find a solution to a problem when we could not
see the problem in the hospital setting. It would have been
helpful to go to different hospitals and see the different styles
of hospital beds and how they have equipment set up to make
sure our device could be compatible with the different
environments. Another issue that arose was that it took a long
time to order and receive parts. As a result, the verification
testing had to be performed later in the process. Moreover,
we went through some changes and iterations later in the
process due to new information and input given to help make
the device perform better.
Something that could be done differently from the
beginning was to keep the device simpler. The attachment of
the first concept device to the bed was over-engineered and
complicated, when there were more simple solutions that
were not only easier to make, but easier for a caregiver to put
in use. We could have focused more on making the device
very easy for the caregiver to operate because if the device
was too complicated it might not be worth purchasing.
Another thing we could have done differently is talk to
more professors, engineers, and stakeholders about our
device and how it works. The more people that we talked to
about our device, the better our design concept became.
Getting other’s input really helped us come up with new
ideas on how to make our device better and we went through
a couple iterations because of it.
XIII.   FUTURE WORK
At the conclusion of this project, it was recognized that
some changes could still be made to more precisely fulfill the
needs of the customer. While many features of the device
satisfied the initial customer requirements per verification
and validation testing, other concepts and designs exist that
could also satisfy these requirements. A key requirement was
that the device prevents entanglement and tension of IV tubes
and other wires. While our multiple slotted design approach
does separate tubes, it does not fully address the tension that
can be put on these tubes. Perhaps a new design could
incorporate a second device with a quick-release mechanism
that is activated upon exceeding a specified amount of
tension. Another requirement was that the device is easy to
use. While the device is simple in structure and function, it
does require multiple steps to attach the device to the bed.
The device could be designed negating the Velcro strap in
favor of an attachment mechanism that only uses one step
such as, for example, a claw-like backing that is flexible
enough to encompass the bed but then sturdy enough to close
around the rail and cannot be easily removed. The Failure
Modes and Effects Analysis can give further insight on future
opportunities to reduce risk. The weight of the device was not
a serious consideration in the initial design so more research
could also be done into lightweight materials that are cost
efficient to manufacture.
XIV. INDIVIDUAL ROLES AND RESPONSIBILITIES
A. Amy Beskitt
Amy Beskitt was responsible for management, Quality
Engineer, and Analyst roles. She conducted stakeholder
interviews with Dr. Thompson and took part in developing
the stakeholder requirements and problem statement from the
interviews. She also completed the phase 1 Quality Function
Deployment in Gate 2 and helped to complete the Design
FMEA in Gate 3. During Gate 4, she completed the
engineering analysis by conducting a Finite Element Analysis
on the prototype and made a Gantt chart to plan the major
task and milestones for Gate 5 and distribute the workload.
She also developed some of the validation plans and
procedures for Gate 5.
B. Abigail Kraft
Abigail had responsibilities in administrative, quality, and
testing engineering roles, She conducted background research
and found existing products to address customer needs. She
also conducted an interview and aided in testing the device at
Akron Children’s Hospital. Abigail played a main role in
developing the conceptual Failure Modes and Effects
Analysis and doing a risk analysis for many potential device
functions. Abigail developed protocols and executed a
majority of the verification testing, gathering data to support
the functionality of the device. Abigail also helped to develop
feasible validation testing ideas. She authored the Design
Verification, Risk Mitigation Process, Future Work, and
Professional and Ethical Responsibilities sections of the
Honors Final Report.
C. Grace Elerick
Grace Elerick was responsible for a mixture of
administrative, regulatory, management, and associated tasks
in the Quality Engineer role. She held one stakeholder
interview and contributed to developing stakeholder
requirements from all interviews. She took part in creating
the Failure Mode and Effects Analysis and multiple QFDs,
including the parts design matrix. Grace was responsible for
all 3D modeling, assemblies, and drawings. She has also
completed work on validating the device and will continue to
do so through the completion of the medical device stage.
D. Zachery Steck
Zach holds responsibilities for the Marketing Research
and Quality Engineer roles. For the first gate review of the
design process Zach was responsible for conducting patent
research for products that met our user needs. In addition to
this, he interviewed a registered flight nurse to learn more
about the needs of critical care patients when confined to the
limited space of a helicopter or ambulance. During the
second gate review of the design process, Zach was partially
responsible for the QFD. He focused on specific competitor
research and ranking against our user requirements. In the
third and fourth gates, Zach was responsible for FMEA
updates, performing all activities related to purchasing, and
market evaluation. He also assisted in validation protocol
writing. Zach authored the academic introduction, user needs,
and marketing and manufacturing considerations sections of
our final paper.
XV.   PROFESSIONAL AND ETHICAL RESPONSIBILITIES
The design of this device was created with many ethical
considerations in mind. On a large scale, this device is
intended to improve patient care by reducing wire
entanglement without obstructing patient care. Our device
was designed to increase patient comfort, mobility, and ease
of transfer. Thus, the device furthers the humanitarian goals
of technology within healthcare. The device also has a
positive economic impact on society in various ways. The
device reduces time spent on non-essential tasks and reduces
the number of personnel needed to transport patients. In this
way, it improves the efficiency of hospitals and healthcare
centers while not sacrificing quality of care. If this device
were produced on a large scale, it should be manufactured to
last at least 5 years. In this way, it is an environmentally
friendly device that will be reused many times and can be
recycled when the lifespan of the device has been reached.
Overall, this device was designed to have a positive global
impact on patients and healthcare workers, fulfilling the
ethical responsibilities of a biomedical engineer.
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Fig. 1. QFD Parts Design Matrix.
Fig. 2. First alpha prototype.
Fig. 3. Second alpha prototype.
Fig. 4 - 7. Drawings of second alpha prototype.
Fig. 4. Prototype Assembly.
Fig. 5. Prototype base.
Fig. 6. Prototype Thumb Slide.
Fig. 7. Prototype Carabiner Rotator.
Fig. 8. Device during validation.
Fig. 9: The Overall Quality Function Deployment Diagram
Tables
Table 2: The risk table shown below was used to assign a risk classification to each failure cause and effect. A severity score was
assigned to the effect of failure and an occurrence score was assigned to the mechanism of failure.
Table 3: A classification code was assigned based on the severity and occurrence scores for each risk.
Table 4: The severity scores used to assess the potential effects of failure.
Severity Scores Possible Description
5 Results in Patient Death
4 Results in permanent patient injury
3 Results in injury or requiring medical attention
2
Results in temporary injury not requiring
medical attention
1 Inconvenience or minor discomfort
Table 5: The occurrence scores used to to assess the probability a mechanism of failure could occur.
Occurrence Rating Probability Range
5 ≥ 10^-3
4 < 10^-3 and ≥ 10^-4
3 <10^-4 and ≥ 10^-5
2 <10^-5 and ≥ 10^-6
1 <10^-6
Table 6: Full list of the Engineering Requirements
Table 7: Validation Plans
Table 8: Procedure for each validation

Table 9: Validation Report
Validation
Procedure No. Validation Name Passed Failed Comments
VP-1 Simulation1 X N/A
VP-2 Simulation2 X N/A
VP-3 Simulation3 X N/A
VP-4 Simulation4 X N/A
VP-5 Inspection X N/A
VP-6 Simulation5 X N/A
VP-7 Market Analysis X N/A
VP-8 Simulation6 X Device was rated 3/5, not meeting the 4/5 requirement.
Table 10: The Risk Summary Table gives an overview of the key risks and how they were mitigated. This includes the name of
risk, risk priority number (RPN), potential risks, risk level, and how risks were mitigated.
Name of Risk Summary of Risk RPN Risk Level Risk Mitigation
Patient/staff trips on
device
Device falls on floor and
patient/staff trips on device
18 AO Make second safety





Fixation or use of device
causes injury to patient or
staff





IV tubes fall out of slots
and pose a tripping hazard
or pull at insertion sites




Device size does not
match the bed size
Device does not fit
properly to bed and injures
patient/staff






Too tight on IV lines and
slows fluids







Device falls or patient
knocks device off bed and
tangles tubing, poses a
tripping hazard and tugs at
insertion sites




Device is broken by
user
Device does not function
properly- device falls, does
not hold tubes injuring
staff/patient
4 AO Detailed instruction
manual included
